NEW
YORK, NY, January 27, 2017 /Sector Newswire/ -- DIAGNOS Inc. (TSX-V: ADK) (US Listing: DGNOF) this week announced the successful
completion of the pilot project for diabetic macular edema and
diabetic retinopathy screening with the Mexican Social Security
Institute. This news falls on the heals of a pilot project with
BAYER Canada. DIAGNOS
is a Canadian-based healthcare software technology company, its
'Computer Assisted Retinal Analysis' (CARA) business applies
artificial intelligence in the diabetes market which non-invasively
identify patients at risk of vision loss. Additionally this week, DIAGNOS
announced the signing of an agreement for the use of CARDS (Computer
Aided Resource Detection Software) to generate mining targets on the
Rocmec1 and Denain properties owned by Nippon Dragon Resources, the
agreement is valued at $70,000 and the results will serve as a guide
for future drilling activities of Nippon Dragon.

DIAGNOS Inc. is expanding globally as a
first-mover in the healthcare retinal analysis sector with proprietary disruptive technology
whose adoption is quickly gaining momentum, doctors and specialists
strongly endorse it as large numbers are non-invasively screened that would otherwise not be
seen. ADK.V's revenue growth curve is rapidly accelerating with
topline >100% Y/Y. Swiss pharmaceutical giant Novartis has become
the Company's biggest customer, initially engaging ADK.V for a
series of pilot 'wellness' programs over the last couple years in various
countries, paying DIAGNOS to screen patients. Recently Novartis has
begun converting pilot programs into contracts, with more on the way
due to the overwhelming success in identifying patients that could
benefit from Novartis' treatment. German pharmaceutical company
Bayer has only recently engaged ADK.V
with similar intentions. DIAGNOS recently signed a contract with an
unnamed pharmaceutical company targeting the US, the world's largest
healthcare market. ADK.V has also started to sell its
solutions to governments on a cost-reduction approach, recently
signing its first government contract in Mexico. Supported by a strong growth and
recurring revenue model, and a low cost growth associated with
its artificial intelligence software, we expect shares of ADK.V to
rise several multiples higher than its current price near-term.

DIAGNOS'
current market cap of ~$23 million Canadian (recently trading at
~$0.18/share) is minuscule compared to
where it appears headed based on contracts in hand, momentum, and
potential. As the reality of the accomplishments and potential are
understood by the marketplace Technology MarketWatch Journal anticipates the share price of ADK.V
will move nearer to 50 cents to better reflect its current inherent
value. Further below is document compelling projected
transaction and revenue numbers; shareholders will appreciate that
the Company's fiscal Q3 (ending December-2016) is expected to show profitability (in Q3 ADK.V
will have booked revenues of ~$1.15M and expenses of ~900K) and the
Company is expected to experience
increasingly robust financials going forward. Patient tests per
month were ~22,000 this October, are expected to be ~26,000 for
November, and are expected to increase to between 60,000 - 70,000
patients per month in 2017. As
impressive as those increases in patient tests are, it is only just the beginning. How big will this
get? The answer is 'we just don't know', but there are numerous
indicators ADK.V is going on a massive run; experts believe
there are ~500 million diabetic individuals worldwide (source: WHO) and the Company's
adoption growth curve for its technology is very early stage. The
Company negotiates its pilots with Pharma so that upfront costs are
covered, ensuring it has a big enough commitment so that DIAGNOS
rarely needs to spend money up front on incremental business. With
four deployment options for its technology, all running at least 55%
margin per transaction, ADK.V has impressive revenue projections
based on committed contracts alone. Future projections are certain
to improve as the level of new inquiries now coming into the Company
and discussions regarding new business from big Pharma, governments,
hospitals, and clinics world-wide now are off the chart. Often there
is lag for new business from initial pilot (dipping their toe) to
commitment (full plunge into larger contract), but as DIAGNOS has
proved with Novartis and the Government of Mexico -- it's a win-win
for everyone to be in business with DIAGNOS. Where this
is headed is truly exciting, the long-term strategy for the Company
is to eventually shift more toward standalone deployment of its technology
(which has highest margins for the Company), with others/partners
carrying the operating costs, and DIAGNOS acting as a centralized
world-wide cloud-based database/processing center (a secure
state-of-the-art facility in Montreal where its
software enhances and analyzes retinal images of patients) handling
large volumes of transactions.

BROSSARD,
QUEBEC--(Marketwired - Jan. 24, 2017) - DIAGNOS Inc.-.("DIAGNOS"
or "the Corporation") (TSX
VENTURE:ADK), a leader in applying Artificial
Intelligence in healthcare technical services
including screening, software and algorithm
development, data analysis, and image processing is
pleased to announce, further to the November 14th,
2016 news release, the successful completion of the
pilot project for the Mexican Social Security
Institute (Spanish: Instituto Mexicano del Seguro
Social, "IMSS"). IMSS provides social security to
over 71 million people nationwide in Mexico.

The pilot project
helped demonstrate that a well-planned wellness
program can have a positive impact on the diabetes
epidemic. DIAGNOS' Artificial Intelligence tools
(CARA) contributed at accurately identifying related
diseases linked to diabetes in 98% of tests
conducted. In order to prevent potential blindness
caused by diabetes, the Corporation believes that
governments must implement new solutions to enable
doctors to be part of the identification process.
Based on our analysis of the situation, it is
estimated that the burden of diabetes today
surpasses $ 96 million Mexican pesos per day
(approx. US $ 5 million dollars).

"We
continue our efforts to provide an integrated
solution through IMSS' flagship diabetes programs "DiabetIMSS"
and "PrevenIMSS". The successful outcome from this
pilot represents an important step towards
implementing soon a multi-annual national screening
project and that would benefit IMSS in taking
control of the high costs associated with diabetes",
said Andrι Larente, President of DIAGNOS.

About CARA
CARA is a tele-ophthalmology platform that
integrates with existing equipment (hardware and
software) and processes at the point of care (POC)
and comprises: image upload, image enhancement
automated pre- screening, grading by a specialist,
and referral to a specialist. CARA's image
enhancement algorithms mak e standard retinal images
sharper, clearer, and easier to read. CARA is
accessible securely over the internet, and is
compatible with all recognized image formats and
brands of fundus cameras, and is EMR compatible.
CARA is a cost-effective tool for screening large
numbers of patients, in real-time and has been
approved by regulatory authorities including Health
Canada, US Food and Drug Administration, European
Union (CE) and COFEPRIS for Mexico.

About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded
Canadian corporation with a mission to commercialize
technologies combining contextual imaging and
traditional data mining thereby improving decision
making processes. DIAGNOS offers products, services,
and solutions to clients in a variety of fields
including healthcare and natural resources.

BAYER Canada and DIAGNOS join efforts against Diabetes

BROSSARD,
QUEBEC--(Marketwired - Dec. 6, 2016) - DIAGNOS Inc.
-.("DIAGNOS"
or "the Corporation") (TSX VENTURE:ADK), a leader in
applying Artificial Intelligence in healthcare
technical services including screening, software and
algorithm development, data analysis, and image
processing, announces today a pilot project contract
for diabetic macular edema and diabetic retinopathy
screening with BAYER Canada. Under the terms of the
agreement, DIAGNOS will provide a fully turn-key
screening service to benefit one thousand diabetic
patients in the Toronto area. Screening will be
offered to diabetics affiliated to their health
entities to test the impact of including preventive
screening programs.

According to the
International Diabetes Federation, diabetic
retinopathy and macular edema are the most common
diabetic eye diseases and the leading cause of
blindness around the world. It is a treatable
disease that, as with most diseases, has a higher
treatment success rate in its earlier stages.
However, there are generally no symptoms until the
disease has progressed to more severe stages, making
early detection methods critical by helping the
prevention of vision loss.

"The
opportunity to partner with Bayer offers an immense
advantage at detecting treatable diabetic
retinopathy using the advanced Artificial
Intelligence technology and eliminating
sight-threatening complications of this disease",
said Netan Choudhry, MD FRCS(C) DABO, director at
DIAGNOS. Mr. Andrι Larente, President of DIAGNOS,
added "We
are excited to start our new commercial relationship
with BAYER in Canada and begin screening for
diabetic macular edema and retinopathy. Following
the expected success of this project, we intend to
expand the scope of services offered through this
pharmaceutical company into other countries."

Nippon Dragon Resources will use DIAGNOS' Artificial
Intelligence tools to optimize exploration of its
Rocmec1 and Denain properties

BROSSARD,
QUEBEC--(Marketwired - Jan. 25, 2017) - DIAGNOS Inc.
-.("DIAGNOS"
or "the Corporation") (TSX VENTURE:ADK), a
leader in applying Artificial Intelligence in data
mining technical services, announces today the
signing of an agreement for the use of CARDS
(Computer Aided Resource Detection Software) to
generate mining targets on the Rocmec1 and Denain
properties owned by Nippon Dragon Resources ("Nippon
Dragon") (TSX VENTURE:NIP). The agreement is valued
at $70,000 and the results will serve as a guide for
future drilling activities of Nippon Dragon.

"The
use of Artificial Intelligence ("AI") is rapidly
growing in all spheres of our lives and the mining
exploration sector definitely needs new powerful
tools to optimize the use of its capital to discover
new mining deposits. The few new discoveries in the
mining world is concerning. In 2016, Google,
Facebook, Microsoft, IBM have exposed us to AI.
DIAGNOS uses and perfected artificial intelligence
since 2000 and is positioned as one of the pioneers
in this industry",
said Mr. Michel Fontaine, Vice-president, Mining of
DIAGNOS.

"The
reports will assist Nippon Dragon in better
understanding the ore bodies and, above all, will
enable us to increase known resources and provide
specific targets for future exploration activities.
New mining technologies such as DIAGNOS' CARDS and
Nippon Dragon's Thermal Fragmentation mining method
make it possible for us to stand out and provide
significant cost savings",
said Donald Brisebois, Nippon Dragon's President and
CEO.

About CARDS
CARDS is a state-of-the-art computer system that
uses powerful algorithms to digitally analyse
publically available as well as privately owned
geological information. For this occurrence, three
data mining techniques based on clustering and
decision tree will be used in order to generate new
targets with a high level of accuracy..

The
Company's retinal analysis analysis business was incepted
in the wake of the downturn in the mining sector
a few years back, DIAGNOS was focused on data
analysis in that sector and made the decision to
springboard off its platform and expertise in
artificial intelligence to build the application
it has now in order to fill the gap between
doctors and specialists. ~Four years ago the
Company launched with zero clients, proved its
concept in 2015 and 2016, and is in 12 countries
with pharmaceutical companies today (10
countries with Novartis). DIAGNOS just became
operational with wellness programs in three new
countries (Nigeria, Kenya, and Malaysia) this
November-2016.

Besides Novartis and Bayer
investing increasingly more capital towards
DIAGNOS, the contacts and introductions that
have been made by pharmaceutical companies in
all those countries to date have themselves
created a flurry of new interest in DIAGNOS that
is expected to translate to additional
opportunity for the Company to expand and gain
additional momentum.

Once DIAGNOS is in a
country it gets introduced to all the government
departments, hospitals, and clinics; DIAGNOS
develops its own contact with them. The first
major government deal with the Mexican
government was recently signed
for ADK.V to screen up to 106,000 diabetics by
year end. DIAGNOS can now rely on larger monthly
revenues. The Latin America market is one of the
largest market for this kind of automated
analysis of medical images.

Saving
vision by reducing congestion at specialists

DIAGNOS sells an
automated system to screen patients for eye diseases. Its system
takes a pictures of a person's eyes, and then uses an artificial
intelligence image-recognition algorithm to assess the patient's
risk of over 20 eye diseases. If it detects a risk, it refers the
patient to a retinal specialist doctor, who prescribes the
appropriate medication or treatment. Because the images can be sent
over the internet, the doctor can be in a different physical
location confirming the diagnostic.
The diseases targeted by the algorithm include the leading causes of
blindness among adults, such as diabetic retinopathy and
aged-muscular degeneration. According to the World Health
Organization, 347 million people have diabetes worldwide (many
experts believe that number is low and actually closer to 500M), of
that number 0.1% of people with diabetes will lose their vision
completely per year if not screened, that translates to 347,000
people per year that will go blind from a curable disease if they
are not screened. These diseases are treatable with
existing medicine but only if caught in the early stage. However,
people at risk are not getting their eyes checked regularly, and
therefore going blind unnecessarily, for the following reasons:A). There is a shortage of retina specialist doctors. There
are just ~1,800 retina specialists in the US versus ~42 million
diabetics. Clinical guidelines suggest that every diabetic be
screened for diabetic retinopathy once a year, obviously impractical
for such a large number to be screened under traditional methods by
so few specialists. In less developed countries the ratio of
specialists to diabetic population is even worse compared to the US
and Canada. By
using an algorithm to screen patients, DIAGNOS ensures that only
those at risk see a doctor, which relieves congestion in the
healthcare system, while improving access to healthcare. B). Seeing a doctor is expensive. Retina specialists can
charge $300 per visit, but DIAGNOS' software driven procedure
charges out at only say ~$20 per visit, and
this fee can be paid by the pharmaceutical company rather than the
patient.C). Seeing a doctor is inconvenient. Retina specialists tend
to be located in urban areas, and therefore may be inaccessible for
rural populations. However, DIAGNOS' system could be installed in
Primary Care Facilities, or stores such as Walgreens and Wal-Mart,
which are beginning to provide low-cost healthcare services, further
improving access to basic healthcare. Theranos Inc., an American
privately held health technology company which
developed a simple blood test that could be deployed in a similar
manner, had signed a partnership agreement with Walgreens and ramped
up to ~$9 billion valuation (Theranos has since had tech issues and
pulled back, unlike Theranos tough DIAGNOS' technology has been able
to withstand rigorous vetting). Often there is also a general lack
of advertising targeting diabetics as to where they can be tested.
Additionally, specialists in some countries are caped by quotas.

Diabetic
Retinopathy is a Treatable Disease

Early detection and treatment
can prevent 85% to 95% of blindness
cases.

The patient may experience no symptoms until the condition is
severe.

People who are unscreened are more likely to: - Present in the ER. - Become blind. - Have other complications.

People who are screened tend to take better care of their diabetes.

The Solution: Early screening using artificial intelligence
software

DIAGNOS' Computer Assisted Retinal Analysis (CARA) Platform -
DIAGNOS already has FDA approval as a medical device. The DIAGNOS solution fills the gap between the doctors and the
specialist. Making the general practitioner able to manage vision
lost for all diabetic patients by having access to this technology.

Regulatory Compliance:

ISO 9001:2008

Certified

ISO 13485:2003

Certified

Canadian Medical Devices Conformity Assessment
System

Certified

Health Canada

Approved
- Class 2 Medical Device

FDA

Approved- Class 2 Medical Device

CE Mark

Approved

Fig. 4CARA screening.

DIAGNOS' test is painless and quick, generally
taking 2 - 3 minutes maximum, its one flash, the company takes the
original image and enhances it to make it easier to read and then
the algorithms do the interpretation.

Having artificial intelligence in the loop to
take care of a very demanding interpretation task that requires a
high degree of proficiency, consistency, and accuracy 24/7 is a
great benefit to specialists. DIAGNOS' software can operate at the
same high level all day long, where as traditional methods rely upon
alertness of humans.

DIAGNOS ends its patient screening session by returning
to the patient a copy of the image of their own eye, either by
email, or smart phone, or a printed copy. That way they can see
inside their own eyes, it makes an impression on the client to be
more conscientious of their health. From the patient's perspective
screening gives a visual representation of how well someone is
managing their diabetes, leading to increased awareness, and
increased compliance with diabetes management.

Economics

Because people are not being screened regularly, they are losing
their vision unnecessarily. This is also a problem for
pharmaceutical companies, since they are missing out on drug sales.
It is estimated that only 30% of people at risk have their eyes
checked on an annual basis. Increasing that rate to 90% would triple
the drug sales, while reducing the number of individuals who go
blind by 85%. This creates a win-win situation for patients and drug
companies. The pharmaceutical companies pay DIAGNOS to screen
people, but make their money back through higher sales of their
patented drugs.

DIAGNOS is aiming to target
hospitals and clinics. Putting a camera in a
clinic with say 12 doctors operating out of it
makes sense; it would allow the doctors to get
results on the spot and provide a higher level
of care for their patients.

------ ------ ------ ------
------ ------

Retina Specialist

 Increased focus on treatable cases.
 Increased revenue.

DIAGNOS does not compete
with specialist as the Company's algos do not
diagnose, they flag patients most at risk with
indicators to see the specialist.

------ ------ ------ ------
------ ------

Pharmaceutical Company

 Increased drug sales volume.

Novartis' main Dibetic
Retinopathy drug is Lucentis, Bayer's is EYLEA,
specialists inject the drug into the eye. The
relationship DIAGNOS has had with Pharma has
been developing over the last 2 - 3 years but
has only now begun to bloom.

[Note: In Canada the drug
companies charge ~C$1,800 for a dose, and once a
patient gets under the drug its 4 to 7 times per
year and treatment averages for ~4 years.]

The old saying "A stitch in
time saves nine" rings true. The cost of
managing diabetic populations that have not been
getting screened properly is exploding. In the
case of Mexico, for example, ~7 years ago
diabetics took up ~6% of the country's medical
budget, now it is ~27% of their medical budget.
Fact is, there is not enough
money and it is endangering the quality of
patient care. DIAGNOS is already working on one
program in Mexico, it is so successful that the
Company expects another contract which it has begun
preliminary work on. Health Services is the
largest ministry in Mexico, they take care of
>8M diabetics. The Company has been requested to
write specifications of service terms
(essentially already done as it will the same as
the first contract it did). No doubt the
Ministry is pleased with DIAGNOS' ability to
curb their budget expenses through wellness
programs.

DIAGNOS has spreadsheets
with analysts in the US, at Medicaid and
Medicare, that show the savings simply from
preventing diabetics going blind, forget
everything else that DIAGNOS can help combat,
the Company can save in the state of Florida
alone over $6 billion over the next 20 years
(Note: DIAGNOS is in proposal stage with Florida
at the moment). It is expected that in 2018
Medicaid and Medicare will be establishing new
guidelines for screening and are expected to be
spending substantial amounts on screening
programs. Government involvement with DIAGNOS
is the big prize for shareholders; when key news
is announced, we anticipate it will act as a
major catalyst that will supplant all current
projections and cause a dramatic upside
revaluation in share price, well above what is
being discussed here today.

------ ------ ------ ------
------ ------

Additional value propositions
stem from interaction with a largely uneducated market; retina screening can be used as an opportunity to educate,
important since less than 10% of people diagnosed with diabetes are
given diabetes self-management training.

Medical Software Has the Mechanics of a Great Business
When mature, DIAGNOS promises to provide investors with a steady
stream of recurring revenues, with minimal maintenance capex
requirements, three hallmarks of a robust business. The revenues are
recurring since people must have their eyes checked annually. Those
at risk, such as diabetics and seniors, are stuck with their
condition for the rest of their lives, which means decades of repeat
sales for DIAGNOS. The sales are reliable because healthcare
providers rarely change application software once it becomes
ingrained in the system, due to high switching costs. Another
strength of DIAGNOS' business model it is scalable and a low
marginal cost of growth, a feature common to other application
software companies. Since the software is developed upfront, the
marginal cost of growth is miniscule, allowing the additional
revenue to fall to the bottom line.

Sunny Macro Supports DIAGNOS
A number of macro tailwinds support the technology's adoption. The
diabetic population is growing at 10% to 12% per year. The
population of seniors and diabetics, two demographics at risk of
blindness-causing eye diseases, continue to grow. These two
demographics also vote, which incentivizes politicians to see the
technology adopted. Companies such as Walgreens and Wal-Mart are looking to offer
low-cost healthcare services in their stores, which could be the
perfect location for a DIAGNOS' system.

With the number of seniors in the world expected to hit one billion
by the end of the decade, charging each $10 to scan the eyes of
every senior means the market will be worth $10 billion per year.
DIAGNOS generated annualized sales of less than $1 million last
year, meaning less than 0.01% of the market has been penetrated. But
the company is growing sales at 300% per year, and the rate of test
per month is increasing, as shown in the table below.

Note the recent dramatic increases in patient
tests month over month; it took a while but all those Pharma pilots
are now converting to contracts
and growing fast. Patient tests per month were ~22,000 this October,
are expected to be ~26,000 for November, and are expected to
increase to between 60,000 - 70,000 patients per month in 2017.

The quarterly sales growth rate has increased
from the past three quarters. Furthermore, DIAGNOS recently signed a
contract with an unnamed pharmaceutical company targeting the US,
the world's largest healthcare market. The company also signed its
first government contract in Mexico and is looking at Latin America
as a large potential market. This suggests the company's sales could be
hitting an inflection point, which could see its
congestion-relieving software gain the critical mass to be globally
adopted.

[*FYI: CARDS stands for 'Computer Aided
Resources Detection System', CARDS revenue comes from the remnants
of DIAGNOS' mining data analysis business which it is phasing out.]

Company
growth year over year including 2018 forecast

Table 3. (Below) Revenue 2015 - 2018. Source: Company disclosures.

DIAGNOS' fiscal year end is in March.
DIAGNOS believes it will hit at least $6.6M in CARA revenue for next
year, that is a conservative low figure, as depending on what it
does in this Q4 the revenues for
next year could very easily
become $10M or $12M. The growth curve is NOT going to
stop as the diabetic population keeps growing and DIAGNOS is so
effective at early screening it is quickly now developing a
reputation as the best option out there.

NOTE: Right now Bayer
is going to be doing a pilot in Canada with DIAGNOS starting in
January 2017, they are going to pay DIAGNOS to screen a small
population of diabetics to see if what has been observed in other
parts of the world are occurring in Canada too. DIAGNOS is confident
the results are going to be the same. DIAGNOS currently has a
program running with Bayer in Columbia right now. What happens with
Bayer is not reflected in the financial projections, however if what
occurred with Novatris' pilots is any indication of what to expect then 2018
projections will have yet another revision upwards.

------ ------ ------ ------ ------ ------

Qualitative Points that Support DIAGNOS' Business
While DIAGNOS has a disruptive healthcare technology that looks
poised to become a robust business, valuing the Company at such an early stage of adoption
for its technology and business model is challenging, especially
with the Company only this fiscal Q3 (ending December-2016)
demonstrating a turn to profitability. An analysis
of qualitative factors provides further support that the shares are
due for significant upward revaluation:

1. FDA approval and
growing sales to Pharmaceutical imply the
technology is effective.

The fact that the FDA has approved the
product, and Novartis + Bayer are paying to
use it (and are upping their capital
investments), confirms that it works.2. Smart money investors already own a
large block of
the shares.
Management and friendly shareholders
(including Dundee: ~18%, Renauld Family: ~8%, Investment partners
NJ: ~8%) own
more than 40% of the outstanding shares.3. No competitors have contracts with
pharmaceutical companies and governments.
While some other companies are developing
similar software systems, DIAGNOS is the
first-to-market and the only one to have a
contract with a major pharmaceutical
companies and government. The presence of
competitors can actually help the adoption
of the technology, as other firms will share
the cost of developing the market. Since
buyers would compare systems anyways,
competitors could prove to be advantageous
for DIAGNOS.

Note: Competitors have
not managed to do what DIAGNOS can do. For
example in the US only one other competitor
has FDA approval on part of their platform,
but they don't have any algorithms to
automatically detect the lesions on the retinas
(that artificial intelligence is the
important piece).4. First solution for government cost
control over diabetes.

By providing an economic model that
demonstrates clearly the saving of wellness
program or prevention programs, to insure
patients dont go blind and carry the
expensive treatment that follows. DIAGNOS
has put together the first economic model to
help governments curve the cost burden of
diabetes.

In contrast to some other names in the
healthcare sector, DIAGNOS' management has been more interested in
running the business than promoting the stock. With the Company's
turn to profitability closing out 2016 and a ramp-up of patient tests
on tap, more attention is headed the Company's way, and we expect
management will dedicate more resources on responsibly relaying its story
to potential investors.

As the company continues to penetrate the >$10Billion dollar market
and revenue explodes to the upside, the company will undoubtedly attract
more
attention from the Pharma companies that sell into that market.
ADK.V
could be a great tuck-in acquisition for large Pharma companies
already selling into the market. Earlier this year, Welch Allyn, an
American medical device maker, bought a competitor to DIAGNOS for an
undisclosed sum. The acquired company, called Hubble Telemedical,
was developing a similar software, but Hubble was a few years behind DIAGNOS (the clear advantage ADK.V has over competition is its
proprietary artificial intelligence algorithms).

------ ------ ------ ------
------ ------

Fig. 6Eyes tell volumes about
cardio vascular health.

DIAGNOS' R&D team is focused on innovation and
evolving the platform.

DIAGNOS is working at a new application that
will evaluate the risk of cardiovascular issues using the same
images as for the retina evaluation.

Future - Cardiovascular: DIAGNOS is working at a new application that will evaluate the risk
of cardiovascular issues using the same images as for the retina
evaluation. The company is focusing on using its technology to help
general doctors in the world by providing real technology tools
based on its artificial intelligence platform. Cardiovascular issues
are affecting most of the population worldwide. The total market
size is $187B in drugs and services.

[FYI: Already 10% of the
market for DIAGNOS that is screened now are
people that are at risk of being diabetic mainly
because they have high blood pressure. If you
have high blood pressure and are 60 years old
and over, then you are at risk of developing
retinopathy.]

------ ------ ------ ------ ------
------

Sector Newswire has identified the
following research links for additional DD on DIAGNOS Inc.:

This release may
contain forward-looking statements regarding future events that
involve risk and uncertainties. Readers are cautioned that these
forward-looking statements are only predictions and may differ
materially from actual events or results. Articles, excerpts,
commentary and reviews herein are for information purposes and are
not solicitations to buy or sell any of the securities mentioned.
Readers are referred to the terms of use, disclaimer and disclosure
located at the above referenced URL(s).